rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Cardiff Oncology, Inc.

CRDF · Nasdaq

Health CareBiotechnologyNot moving yet

CRDF stood above a rising 150-day average in 0 of the last 52 weekly readings. It is 33.4% below that average now. Biotechnology: 16% of its 561 stocks in an uptrend (−15 points in four weeks); Health Care: 26% (−10 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 52
Industry in uptrend
16% -15 in 4 wk
Insider buys, 12 months
$2.2M
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
101 (-9)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 0 of 52 weeks.

20 Apr – 19 Oct
17%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$2.0MNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months4
Sale orders, 12 months0
Buyers · sellers2 · 0
WhoDidSharesTraded
Mani MohindruChief Executive Officerbought34,364at $1.4614 Jul 2026filed 16 Jul 2026
Mani MohindruChief Executive Officerbought34,364at $0.0014 Jul 2026filed 16 Jul 2026
Gary W. PaceDirectorbought687,285at $1.4614 Jul 2026filed 16 Jul 2026
Gary W. PaceDirectorbought687,285at $0.0014 Jul 2026filed 16 Jul 2026
Gary W. PaceDirectorbought30,000at $1.2218 Jun 2026filed 22 Jun 2026
Mani MohindruChief Executive Officerbought24,703at $1.2118 Jun 2026filed 22 Jun 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders101-9 on the quarter
New · exited22 · 31
Reported value$23.3M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
Laurion Capital Management LPadded · filed 13 Aug 20263,098,299$4.0M+451,561+17.1%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20262,895,592$3.8M+39,626+1.4%
Pfizer Incunchanged · filed 13 Aug 20262,411,575$3.0M00.0%
FRANKLIN RESOURCES INCunchanged · filed 13 Aug 20261,205,803$1.6M00.0%
BlackRock, Inc.reduced · filed 7 Aug 2026972,873$1.3M-3,008,514−75.6%
BLAIR WILLIAM & COreduced · filed 11 Aug 2026912,513$1.2M-9,894−1.1%
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 2026820,062$1.1M-779,601−48.7%
UBS Group AGadded · filed 13 Aug 2026638,699$830K+238,123+59.4%
JANE STREET GROUP, LLCadded · filed 14 Aug 2026607,900$790K+567,795+1415.8%
VANGUARD FIDUCIARY TRUST COreduced · filed 13 Aug 2026410,602$534K-35,623−8.0%
31 Mar 2023 – 30 Jun 2026
4878108Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Gary W. Pace Company insiderDirector · last 14 Jul 202613 · 0
Mani Mohindru Company insiderChief Executive Officer · last 14 Jul 20262 · 0
James O. Armitage Company insiderDirector · last 11 Jun 20263 · 0
Lale White Company insiderDirector · last 11 Jun 20262 · 0
Renee P. Tannenbaum Company insiderDirector · last 11 Jun 20262 · 0
Rodney S. Markin Company insiderDirector · last 11 Jun 20264 · 0
Ajay Aggarwal Company insiderChief Operating Officer · last 27 Apr 20260 · 0
Tod Smeal Company insiderChief Scientific Officer · last 14 Apr 20260 · 0
Joshua B. Muntner Company insiderChief Financial Officer · last 6 Apr 20260 · 0
Brigitte Ute Lindsay Company insiderChief Accounting Officer · last 13 Feb 20260 · 0
Fairooz Kabbinavar Company insiderChief Medical Officer · last 11 Mar 20250 · 0
James E. Levine Company insiderChief Financial Officer · last 11 Mar 20255 · 0

Same industry

MRNA ModernaLeading+154%
ENTX Entera BioLeading+49%
XNCR XencorLeading+32%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2025 · to 31 Dec 2025-108%
Share count trendFY 2025 · to 19 Feb 20260.1%
Cash and equivalentsFY 2025 · to 31 Dec 2025$17.5M
Free cash flowFY 2025 · to 31 Dec 2025−$38.0M

Analyst forecasts

No analyst forecasts yet.